Tranexamic acid-13C6

Tranexamic acid-13C6 (Cyclocapron-13C6) is 13C labeled Tranexamic acid. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis [1][2][3][4][5].

Product Specifications

Product Name Alternative

Cyclocapron-13C6

UNSPSC

12352211

Target

AMPK; IGF-1R; Isotope-Labeled Compounds; Mitophagy; MMP

Related Pathways

Autophagy; Epigenetics; Metabolic Enzyme/Protease; Others; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease; Cardiovascular Disease

Smiles

O=C([13C@]1[13C][13C][13C@](CN)[13C][13C]1)O

Molecular Formula

C2 13C6H5NO2

Molecular Weight

153.09

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Prudovsky I, et al. Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation [J]. Journal of cellular physiology, 2019, 234 (11) : 19121-19129.|[3]Wu G, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator [J]. Blood advances, 2019, 3 (5) : 729-733.|[4]Draxler D F, et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis [J]. Journal of Thrombosis and Haemostasis, 2019, 17 (12) : 2174-2187.|[5]Hiramoto K, et al. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness [J]. Biomedicine & Pharmacotherapy, 2016, 80: 16-22.|[6]Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery [J]. New England Journal of Medicine, 1989, 320 (13) : 840-843.